Contraindications: Oxymetholone is contraindicated in individuals with diagnosed hepatic impairment, prostate or breast carcinoma, hypersensitivity to 17α-alkylated androgens, or active cardiovascular disease. Women who are pregnant or may become pregnant must not use this compound. Adolescents and individuals with elevated baseline haematocrit values should not initiate a frontloading protocol with Oxymetholone.
Side_Effects: Hepatotoxicity is the primary concern with oral 17α-alkylated androgens; ALT and AST elevation is expected and accelerates with dose and duration. Fluid retention and rapid bodyweight increase during the kickstart phase may mask strength-to-mass ratios. Androgenic effects including acne, scalp hair thinning and increased sebum production are reported. Haematocrit elevation during the erythropoietic phase increases blood viscosity risk and requires monitoring.
Monitoring: Obtain liver function tests (ALT, AST, GGT) and a full blood count including haematocrit at baseline and at week 2 of the kickstart block. Haematocrit exceeding the laboratory's upper reference limit warrants immediate dose review. Lipid panel (LDL, HDL) should be assessed, as oral androgens suppress HDL measurably. Blood pressure monitoring throughout the kickstart phase is recommended given the fluid-retention component.
PCT: Post-Cycle Therapy following a kickstart-plus-injectable cycle must address suppression from the full cycle, not the oral phase alone. SERM-based PCT (Tamoxifen or Clomiphene) should commence based on the long-ester injectable's clearance timeline, not Oxymetholone's, since the injectable governs residual androgenic suppression at cycle end.